So it’s farewell to 2021 – a year that promised little and delivered less

If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype.

As predicted, there was little movement in many of the major issues controlling the CBD market – in particular the continued lack of regulatory clarity regarding the use of CBD in ingestible products showed no sign of change.

Across the EU, UK and US, regulators failed to make much headway in creating a pathway to market for CBD ingestible products.